Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

CARM

Carisma Therapeutics (CARM)

Carisma Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:CARM
일자시간출처헤드라인심볼기업
2024/06/2520:30PR Newswire (US)Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid TumorsNASDAQ:CARMCarisma Therapeutics Inc
2024/06/2520:30PR Newswire (US)Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy ForumNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1908:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1505:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1505:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
2024/06/1405:30PR Newswire (US)Carisma Therapeutics Announces Adjournment of Annual Meeting of StockholdersNASDAQ:CARMCarisma Therapeutics Inc
2024/06/0600:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
2024/06/0600:45Business WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
2024/05/3020:30PR Newswire (US)Carisma Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:CARMCarisma Therapeutics Inc
2024/05/2908:39Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CARMCarisma Therapeutics Inc
2024/05/1620:30PR Newswire (US)Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-MonocyteNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0920:52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARMCarisma Therapeutics Inc
2024/05/0920:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0920:30PR Newswire (US)Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0900:45Business WireCarmila: Withdrawal of funds for the liquidity contractNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0900:45Business WireCarmila: Réduction des moyens du contrat de liquiditéNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0820:30PR Newswire (US)Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024NASDAQ:CARMCarisma Therapeutics Inc
2024/05/0800:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0800:45Business WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0620:30PR Newswire (US)Carisma Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceNASDAQ:CARMCarisma Therapeutics Inc
2024/05/0220:30PR Newswire (US)Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical OfficerNASDAQ:CARMCarisma Therapeutics Inc
2024/04/2506:05PR Newswire (US)Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingNASDAQ:CARMCarisma Therapeutics Inc
2024/04/2501:43Business WireCarmila: Launch of a Share Buyback Program for €10 MillionNASDAQ:CARMCarisma Therapeutics Inc
2024/04/2501:43Business WireCarmila : Lancement d’un programme de rachat d’actions pour 10 millions d’eurosNASDAQ:CARMCarisma Therapeutics Inc
2024/04/2305:35PR Newswire (US)Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingNASDAQ:CARMCarisma Therapeutics Inc
2024/04/1800:45Business WireCarmila : Information financière au 31 mars 2024NASDAQ:CARMCarisma Therapeutics Inc
2024/04/1800:45Business WireCarmila: First-quarter 2024 Financial InformationNASDAQ:CARMCarisma Therapeutics Inc
2024/04/0600:45Business WireCarmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
2024/04/0600:45Business WireCarmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
2024/04/0320:00PR Newswire (US)Carisma Therapeutics to Present at Upcoming ConferencesNASDAQ:CARMCarisma Therapeutics Inc
 검색 관련기사 보기:NASDAQ:CARM